Literature DB >> 20235788

Haplotypes of the adrenergic system predict the blood pressure response to beta-blockers in women with essential hypertension.

Fabiana Filigheddu1, Giuseppe Argiolas, Simona Degortes, Roberta Zaninello, Francesca Frau, Silvia Pitzoi, Emanuela Bulla, Patrizia Bulla, Chiara Troffa, Nicola Glorioso.   

Abstract

AIMS: To analyze the association of haplotypes of the adrenergic system with essential hypertension and with the blood pressure response to beta-blockers. MATERIALS &
METHODS: In 1112 never-treated essential hypertension patients and 203 normotensive controls, tightly linked SNPs of beta-adrenergic receptors (ADRB1 - Ser49Gly and Arg389Gly; ADRB2 - Cys19Arg, Gly16Arg and Gln27Glu) and the G-protein beta3-subunit (GNB3 - A3882C, G5249A and C825T) were genotyped. Association of haplotypes with essential hypertension and with the blood pressure response to atenolol 50 mg twice daily in a subgroup of essential hypertension patients (n = 340) was evaluated (Haploview 3.2).
RESULTS: No SNPs or haplotypes were associated with essential hypertension. In females only, GNB3 SNPs and haplotypes were associated with the blood pressure response (p < 0.05).
CONCLUSION: Our study confirmed the sex-specific association of GNB3 with the blood pressure response to atenolol with no substantial advantage of the analysis of haplotypes over SNPs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20235788     DOI: 10.2217/pgs.09.158

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  8 in total

Review 1.  Cardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directions.

Authors:  J A Johnson; S B Liggett
Journal:  Clin Pharmacol Ther       Date:  2011-02-02       Impact factor: 6.875

Review 2.  Genomics and Pharmacogenomics of Salt-sensitive Hypertension.

Authors:  Ines Armando; Van Anthony M Villar; Pedro A Jose
Journal:  Curr Hypertens Rev       Date:  2015

Review 3.  An update on the pharmacogenetics of treating hypertension.

Authors:  V Fontana; M R Luizon; V C Sandrim
Journal:  J Hum Hypertens       Date:  2014-08-28       Impact factor: 3.012

4.  Genomics and pharmacogenomics of salt-sensitive hypertension Minireview.

Authors:  Ines Armando; Van Anthony M Villar; Pedro A Jose
Journal:  Curr Hypertens Rev       Date:  2015

5.  Variants in ADRB1 and CYP2C9: Association with Response to Atenolol and Losartan in Marfan Syndrome.

Authors:  Sara L Van Driest; Lynn A Sleeper; Bruce D Gelb; Shaine A Morris; Harry C Dietz; Geoffrey A Forbus; Elizabeth Goldmuntz; Arvind Hoskoppal; Jeanne James; Teresa M Lee; Jami C Levine; Jennifer S Li; Bart L Loeys; Larry W Markham; Josephina A N Meester; Seema Mital; Jonathan D Mosley; Aaron K Olson; Marjolijn Renard; Christian M Shaffer; Angela Sharkey; Luciana Young; Ronald V Lacro; Dan M Roden
Journal:  J Pediatr       Date:  2020-07       Impact factor: 4.406

Review 6.  Personalized medicine and treatment approaches in hypertension: current perspectives.

Authors:  James Brian Byrd
Journal:  Integr Blood Press Control       Date:  2016-04-06

Review 7.  Pharmacogenomics of Hypertension Treatment.

Authors:  Jacek Rysz; Beata Franczyk; Magdalena Rysz-Górzyńska; Anna Gluba-Brzózka
Journal:  Int J Mol Sci       Date:  2020-07-01       Impact factor: 5.923

8.  Mapping genetic variants associated with beta-adrenergic responses in inbred mice.

Authors:  Micha Hersch; Bastian Peter; Hyun Min Kang; Fanny Schüpfer; Hugues Abriel; Thierry Pedrazzini; Eleazar Eskin; Jacques S Beckmann; Sven Bergmann; Fabienne Maurer
Journal:  PLoS One       Date:  2012-07-31       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.